Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered t cells with a kill switch aim to make stem cell transplants safer

NCT ID NCT00710892

NEW Ongoing Disease control Sponsor: Baylor College of Medicine Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 01, 2026

Summary

This study tests a new approach for people receiving a stem cell transplant from a partially matched family donor. The donor's immune cells (T cells) are modified in the lab to include a 'suicide gene' that can be activated by a drug if the cells attack the patient's body, causing graft-versus-host disease (GvHD). The goal is to see if higher doses of these modified T cells can help the immune system recover faster while keeping GvHD under control. The trial involves 10 patients with blood cancers or related disorders.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

allodepleted T cells with inducible caspase 9 suicide gene

What this could lead to

If it works, this could allow safer use of partially matched donor stem cells by giving doctors a way to turn off immune cells that attack the patient's body.

What could go wrong

This is a very early phase 1 trial with only 10 participants. The suicide switch has not been proven to work in humans, and patients who develop graft-versus-host disease will still need standard treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia chronic myelogenous leukemia, BCR-ABL1 positive hemophagocytic syndrome hereditary hemophagocytic lymphohistiocytosis histiocytic sarcoma immunodeficiency 32B Leukemia, Myelogenous, Chronic, BCR-ABL Positive Lymphohistiocytosis, Hemophagocytic lymphoproliferative syndrome myelodysplastic syndrome Myelodysplastic Syndromes non-Hodgkin lymphoma Precursor Cell Lymphoblastic Leukemia-Lymphoma secondary hemophagocytic lymphohistiocytosis X-linked lymphoproliferative syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA CHRONIC MYELOID LEUKEMIA MYELODYSPLASTIC SYNDROME NON-HODGKIN'S LYMPHOMA

Contacts and locations

Locations

  • Texas Children's Hospital

    Houston, Texas, 77030, United States

  • The Methodist Hospital

    Houston, Texas, 77030, United States